The public offerings by immuno-oncology-focused Forty Seven Inc., which is developing anti-CD47 antibodies against a number of cancers, and Jerusalem-based Entera Bio Ltd. Thursday brought the number of biopharma companies graduating to the U.S. public ranks to 14 this month. According to BioWorld's public financings database, you have to travel back to August 2000 for a higher monthly total when 17 companies went public. Read More
Last year the Institute for Alternative Futures published results from its updated diabetes (type 1 and type 2) forecasting model, extending its projections to 2030. The data show that diabetes will remain a major health crisis in the U.S., with the prevalence of diabetes increasing by 54 percent to more than 54.9 million people. Read More
